Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM180DM)

Drug Name

ARGX-113 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Myasthenia gravis	8C6Y	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neonatal Fc receptor (FCGRT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Efgartigimod alfa	DM2M93X	Myasthenia gravis	8C6Y	Approved	[3]
Batoclimab	DMYPMR8	Myasthenia gravis	8C6Y	Phase 3	[4]
Nipocalimab?	DM0DYAX	Chronic inflammatory demyelinating polyneuropathy	8C01.3	Phase 3	[5]
SYN-1327	DMFNR75	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03770403) A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+). U.S. National Institutes of Health.
2	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673.
3	FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761195.
4	Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2023 Jan;30(1):195-203.
5	New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia. Transfus Med Rev. 2022 Oct;36(4):175-180.
6	Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem. 2008 Jun 15;16(12):6394-405.